A recent Glaxosmithlline Intellectual Property (No 4) Ltd. and Ideaya Biosciences Inc. patent describes the development of thiadiazolyl derivatives acting as DNA polymerase θ (POLQ) inhibitors reported to be useful for the treatment of cancer.
Nicoya Therapeutics (Shanghai) Co. Ltd. has reported the identification of compounds acting as dual endothelin ETA receptor and angiotensin AT1 receptor antagonists.
S-Adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors have been described in an Insilico Medicine IP Ltd. patent as potentially useful for the treatment of cancer.
Immunophage Biomedical Co. Ltd. have prepared and tested G-protein coupled receptor 183 (GPR183; EBI2) antagonists that are reported to be useful for the treatment of autoimmune disease, cancer, liver diseases, osteoporosis and neuropathic pain.
Pyrimidopyridine derivatives acting as GTPase KRAS G12D inhibitors have been reported in a Sunshine Lake Pharma Co. Ltd. patent as potentially useful for the treatment of cancer.
Beijing Tide Pharmaceutical Co. Ltd. has prepared proteolysis-targeting chimera (PROTAC) compounds comprising an ubiquitin ligase binding moiety bound to a protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) targeting moiety through a linker.
RSS